Aller au contenu
forum sidasante

**[SIDA] : le "VIH" ne cause pas le SIDA ** 2/3


Recommended Posts

Invité kanada

Bonjour Terry,

J'entends bien ton message. Pourtant il faut condamner. Pas les gens... mais les actes !

Nous sommes certainement nombreux à avoir des amis allemands, pourtant, nous ne pardonnerons jamais les exactions de la guerre de 40.

Il en va de même pour tout : l'aveuglement médical actuel est condamnable : on patauge à soulager les gens mais on ne sait pas ce qui déclenche les malaises... Nous devons condamner l'acharnement thérapeutique, nous devons par nos coups de gueule soutenir le courage des quelques médecins qui disent : peut-être que le remède est pire que le mal... etc

C'est malheureusement comme ça qu'on avance le plus vite : on condamne une pratique, on identifie ses auteurs, et on discute pour faire changer les choses... Sinon, c'est la pensée unique qui triomphe sur le dos de la majorité silencieuse.

A bientôt


PS : je complèterai mon témoignage quand je trouverai le temps, je n'oublie pas.

Lien vers le commentaire
Partager sur d’autres sites

  • Réponses 1,1k
  • Created
  • Dernière réponse

Top Posters In This Topic

Voici ce que l'on disait de l'AZT en 1993, avant l'apparition de la lamivudine :

étrange comme ces propos semblent sortir de la bouche de Peter Duesberg ou d'autres... n'est pas question malgré tout de se remettre en cause.

Lien vers le commentaire
Partager sur d’autres sites

Pour ceux qui lisent l'anglais, voilà un commentaire édifiant provenant d'un fabricant de tests "vih" :

Why have rapid tests acquired a bad reputation during the last few years ?

Reason 1:Inherent problems with the detection systems, low degree of production standardization and handling problems

The WHO-listing of rapid HIV-assays is long. However, most of these assays are no more in use and a large number of them have phased out of the market. The main reason is that they were all burdened with inherent problems associated with their detection systems (colloidal gold, latex particle aggregation or solid phase enzyme reaction). These test are sensitive to the climate of developing countries, they exhibit strong variations in quality from lot to lot and are susceptible to over-exposure, thus causing false positive reactions. Consequently, GAIFAR decided to take on the difficult task of developing a completely new detection system (OCA-particles, see above) which eliminates the above problems and increases substantially the sensitivity of its tests. 

Furthermore, many of these assays were produced by small companies that could not afford the elaborate quality control systems required for production approval in accordance with local laws and the WHO-GMP (good manufacturing practice) standards. Such approvals were obtained by GAIFAR and the process took almost 1.5 years to complete. 

Furthermore, the problem of obtaining a drop of blood has not been solved in most cases. Usually, a plastic pipette is used. Even if one gets the often-required 50 microliters of blood out of a finger-prick, the blood is then attached to the inner walls of the pipette and cannot easily be released into the test device. It is therefore not possible to separate the process of blood sampling from the performance of the test. Besides, in the framework of mass testing, this is crucial in order to ensure confidentiality of the testing and counseling processes. GAIFAR is therefore using a heparinized capillary to obtain blood in the waiting area. This blood-filled capillary is then put into the mixing vial thus allowing the safe transport of the vial to a separate testing area. This way, the test is performed outside the view of waiting friends and relatives. By so doing, 5-10 samples can be collected and tested simultaneously within 3-5 minutes.

Reason 2: To many false positive and false negative results

Many of the colloidal gold assays, for example, continue to develop even after the development time of 15-20 minutes has passed. This causes a phenomenon which virtually excludes such assays from being used in developing countries. They have the tendency of turning all tests into false positive. How can anyone expect people in rural areas to time exactly a test reaction and disregard the opposite result after the development time has elapsed ? GAIFAR has therefore developed both a new detection system (OCA-particles) and test formats which prevent the occurrence of false positive results, even if the developed test is left for a prolonged period.

In addition, false positive reactions do often occur with unacceptable frequency if such tests are read within the allowed development time frame. This is due to the binding of cross-reacting antibodies to the HIV-proteins used. The sensitivity and specificity data which have been reported for many of the assays used in the past were actually obtained with blood and sera of people from developed countries. Such data are often misleading. The reason is that the diseases which cause the occurrence of cross-reacting or polyreactive antibodies such as malaria, tuberculosis and hepatitis are rare in these countries. GAIFAR has therefore taken the complex andlaborious task to commit a large group of molecular biologists to design, clone, express and purify epitope-combi antigens for each HIV-protein. Among other advantages, such epitope-combi antigens lack sequences which cause unspecific reactions.

In order to avoid false negative results, the sensitivity of the tests has to be high. But this is not enough. The test should equally recognize all strains of HIV. However, most tests that have been developed were using HIV-strains which are prevalent in the developed countries. Consequently, they have been tested with sera and blood samples from these regions. Therefore, the chance of missing a substantial number of HIV-infected people in developing countries is high. 

In order to address these problems, GAIFAR has used large databanks containing the sequences of hundreds of HIV-variants and identified those sequences which are conserved among the variants of one HIV-strain and which are different from others. This way, epitope-combi antigens were created which even allow the strong recognition of the most rare and unusual type of HIV such as the O-strain.

Reason 3: The lack of confirmation and differentiation assays

There is still a major ethical problem even if there is higher precision of the previous screening assays. How can one look into the eyes of another person and claim that he or she is HIV-positive? In this context, it is interesting to note that the current criteria for the acceptance of rapid assays in the developed countries tolerate for up to 1.5 % false positive results. However, nobody in these countries will ever accept this ambiguity in the final result. Therefore, no patient is informed about the result of the screening assay until a Western Blot confirmation test or other reliable confirmation assays (e.g. PCR) have been performed and found positive.

This is not the case in developing countries, including such countries as South Africa which have a relatively high standard among important segments of their health care system. Confirmation of a positive result is made by using one or two other screening assays. This is also true for tests performed in diagnostic laboratories. However, nearly all current producers of screening assays use variants of one HIV-protein named gp41. This means that the same kind test is performed two to three times. The only difference is the brand name.

On the other hand, a true positive reaction may be detected by one of these screening assays and missed by the other one which is less sensitive. Again, this approach causes massive confusion and raises ethical problems in connection with HIV-testing in developing countries.

Easy access of laboratory based confirmation assays is outside the reach of developing countries because of the high price per test performed. The required logistics including thetransportation of the samples from rural areas to laboratories is extremely complicated. This situation is further compounded by the lack of skilled personnel to handle the elaborate processes.

Therefore, GAIFAR has developed the first worldwide rapid Western Blot-type confirmation assay for HIV-1 and a supplemental assay which allows the differentiation between HIV-1 and HIV-2 (InstantConfirm and DoubleCheck, see above). The combination of these tests with the screening tests such as the ultra-rapid InstantScreen is now allowing for the first complete HIV-diagnosis to be made on the spot - be it in a doctors office or under a shade tree.

It is now apparent that the major ethical bias against rapid tests for HIV is been eliminated since the scientific quality of the combined results of these three sets of tests is exactly the same as one obtained in laboratories in developed countries. For the first time,health care professionals can look straight into the eyes of a patient and counsel him/her in an ethically acceptable way.

Another important factor in the GAIFAR set of diagnostics is that it is now possible to identify an HIV-2 infection, a condition which will lead to AIDS much later than it is usually observed with HIV-1. An infection with HIV-2 can now be made known to a patient in order to give him or her a glimmer of hope for a longer life. 

Equally important, in particular in West-Africa, is the fact that the patient can be informed about a possible HIV-2 infection, a condition which will lead to AIDS much later than it is usually observed with HIV-1. In the absence of a therapy option in most African countries, this information is an ethical obligation to the patient because it will change his view on life and his coping strategies dramatically. 

manifestement, en dehors de la volonté qu'ils ont de mettre leur test sur le marché, ces gens-là ne se posent jamais de question, les doigts sur la couture du pourtant, leurs propos sont vraiment limite...dissident, même s'ils ne s'en rendent pas compte.

Lien vers le commentaire
Partager sur d’autres sites

Un document intéressant de 1993, qui montre qu'à cette époque le doute était beaucoup plus autorisé que maintenant. On voit bien que la réussite surprise de la lamivudine en 1995 a changé la donne et permis aux tenants de l'hypothèse virale de prendre la main :

Modifié par Cheminot
Lien vers le commentaire
Partager sur d’autres sites

Une grande nouvelle venant d'Afrique du Sud :

la haute cour de justice a débouté le TAC de ses plaintes contre le gouvernement et les personnes qui soignent le sida autrement. Evidemment, personne n'en a parlé dans nos médias occidentaux.

Le TAC est même accusé de répandre la maladie et la mort dans le peuple sud-africain, et de miner la démocratie.

Mauvais point pour Nathan Neffgen et son "Harper's Rebuttal"

Lien vers le commentaire
Partager sur d’autres sites

Oui, Cheminot, voilà une nouvelle fabuleuse ! L'orthodoxie du sida vient de subir une bien cuisante défaite.

Et quand je lis l'article auquel tu renvois, il est notamment précisé que statistiquement, la plupart des sud-africains prenant des drogues dites "antivirales" meurent ..... dans les quatre ans ! Mais sinon, à part ce "détail", les tri"thérapies" font du bien en Afrique du Sud ?! reflechi.gif

Peut-on maintenant espérer que grâce à cette décision de justice historique, le gouvernement sud-africain aura enfin les coudées franches pour bouter hors du pays toute cette orthodoxie du sida et toutes leurs drogues dites "antivirales" ?

J'ose l'espérer. Et en plus, cela aura un effet absolument dévastateur sur l'orthodoxie du sida. Il me semble impossible que la presse ne puisse pas en parler dans de telles circonstances.

Lien vers le commentaire
Partager sur d’autres sites

Wallypat, je suis pourtant étonné que les sites sceptiques américains n'en aient pas encore parlé (Aidsmythexposed), ni Anthony Brink sur Aidssoc (yahoo). Je vais étudier cela d'un peu plus près.

Lien vers le commentaire
Partager sur d’autres sites

A la suite d'un article paru dans Harper's, mensuel de gauche américain, et écrit par Célia Farber, le TAC antimbeki, par la voix de Nathan Neffgen et avec la signature de Robert Gallo a écrit une réfutation des dires de Celia Farber.

Voici la réponse du groupe "Rethinkingaids" (formé en particulier d'Etienne de Harven, de David Rasnick, Christian Fiala,...).

intéressante également, et venant du site du TAC, cette news

Modifié par Cheminot
Lien vers le commentaire
Partager sur d’autres sites